Diagnostic Performance of the Modified Lung CT Screening Reporting and Data System in a TB-Endemic Country: The Korean National Lung Cancer Screening Program.

IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE
Chest Pub Date : 2025-01-28 DOI:10.1016/j.chest.2025.01.020
Hyungjin Kim, Eunseo Jo, Jinseob Kim, Nayoung Lee, Jin Mo Goo, Yeol Kim
{"title":"Diagnostic Performance of the Modified Lung CT Screening Reporting and Data System in a TB-Endemic Country: The Korean National Lung Cancer Screening Program.","authors":"Hyungjin Kim, Eunseo Jo, Jinseob Kim, Nayoung Lee, Jin Mo Goo, Yeol Kim","doi":"10.1016/j.chest.2025.01.020","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In 2019, Korea initiated the world's first national low-dose CT imaging lung cancer screening (LCS) program, adapting the Lung CT Screening Reporting and Data System (Lung-RADS) to counteract the high false-positive rates driven by prevalent TB.</p><p><strong>Research question: </strong>Does the modified Lung-RADS enhance screening specificity while maintaining sensitivity?</p><p><strong>Study design and methods: </strong>This nationwide, retrospective cohort study included high-risk individuals 54 to 74 years of age with active tobacco use of at least 30 pack-years participating in the national LCS program from 2019 through 2020. The modified Lung-RADS 1.0 introduced category 2b for nodules matching the size of categories 3 or 4, but showing benign features like granulomas and juxtapleural nodules, and enhanced details for category 4X. Lung cancer diagnosis rates within 1 year of screening and the diagnostic performance of the modified and original Lung-RADS were evaluated.</p><p><strong>Results: </strong>Among 152,918 participants (98.2% male; mean [SD] age, 61.7 [5.3] years), lung cancer was diagnosed in 0.68% of participants (1,047 of 152,918). A linear trend in cancer rates across Lung-RADS categories was noted (P < .001). Category 2b showed a higher cancer rate than category 2 (0.25% [45 of 18,120] vs 0.14% [33 of 23,467]; P = .01), but lower than category 3 (0.53% [37 of 7,009]; P = .001). Category 4X showed a cancer rate of 36.88% (416 of 1,128). The modified Lung-RADS demonstrated improved specificity (91.96% [139,664 of 151,871] vs 80.06% [121,589 of 151,871]; P < .001) compared with the original criteria. Although sensitivity showed a modest decrease (81.9% [858 of 1,047] vs 86.2% [903 of 1,047]; P < .001), the modification substantially reduced the follow-up burden, decreasing the number of positive screening results needed to detect 1 case of cancer from 34.5 to 15.2. The positive predictive value improved significantly (from 2.90% [903 of 31,185] to 6.57% [858 of 13,065]; P < .001), whereas the negative predictive value remained consistently high (modified, 99.86% [139,664 of 139,853] vs original, 99.88% [121,589 of 121,733]; P = .23).</p><p><strong>Interpretation: </strong>Korea's modified Lung-RADS enhanced screening efficiency through improved specificity, despite a small reduction in sensitivity.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2025.01.020","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In 2019, Korea initiated the world's first national low-dose CT imaging lung cancer screening (LCS) program, adapting the Lung CT Screening Reporting and Data System (Lung-RADS) to counteract the high false-positive rates driven by prevalent TB.

Research question: Does the modified Lung-RADS enhance screening specificity while maintaining sensitivity?

Study design and methods: This nationwide, retrospective cohort study included high-risk individuals 54 to 74 years of age with active tobacco use of at least 30 pack-years participating in the national LCS program from 2019 through 2020. The modified Lung-RADS 1.0 introduced category 2b for nodules matching the size of categories 3 or 4, but showing benign features like granulomas and juxtapleural nodules, and enhanced details for category 4X. Lung cancer diagnosis rates within 1 year of screening and the diagnostic performance of the modified and original Lung-RADS were evaluated.

Results: Among 152,918 participants (98.2% male; mean [SD] age, 61.7 [5.3] years), lung cancer was diagnosed in 0.68% of participants (1,047 of 152,918). A linear trend in cancer rates across Lung-RADS categories was noted (P < .001). Category 2b showed a higher cancer rate than category 2 (0.25% [45 of 18,120] vs 0.14% [33 of 23,467]; P = .01), but lower than category 3 (0.53% [37 of 7,009]; P = .001). Category 4X showed a cancer rate of 36.88% (416 of 1,128). The modified Lung-RADS demonstrated improved specificity (91.96% [139,664 of 151,871] vs 80.06% [121,589 of 151,871]; P < .001) compared with the original criteria. Although sensitivity showed a modest decrease (81.9% [858 of 1,047] vs 86.2% [903 of 1,047]; P < .001), the modification substantially reduced the follow-up burden, decreasing the number of positive screening results needed to detect 1 case of cancer from 34.5 to 15.2. The positive predictive value improved significantly (from 2.90% [903 of 31,185] to 6.57% [858 of 13,065]; P < .001), whereas the negative predictive value remained consistently high (modified, 99.86% [139,664 of 139,853] vs original, 99.88% [121,589 of 121,733]; P = .23).

Interpretation: Korea's modified Lung-RADS enhanced screening efficiency through improved specificity, despite a small reduction in sensitivity.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Chest
Chest 医学-呼吸系统
CiteScore
13.70
自引率
3.10%
发文量
3369
审稿时长
15 days
期刊介绍: At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信